Liang, Yang, Yang, Lin‐Hai, Jiang, Hui, Yuan, Xiao‐Jun, Sun, Li‐Rong, Wang, Ning‐Ling, and Tang, Jing‐Yan
This multicenter study used the Shanghai Children's Medical Center ( SCMC)- ALL-2005 protocol for treatment of young patients (<2 years old) with acute lymphoblastic leukaemia ( ALL), which was designed to improve treatment outcome in Chinese paediatric patients. These aims were pursued through risk-directed stratification based on presenting clinical and genetic features, minimal residual disease ( MRD) levels and treatment response. All the patients achieved completed remission with 5-year event-free survivals of 82·6 ± 9·7% (low risk), 52·6 ± 8·4% (intermediate risk), 28·6 ± 17·1% (high risk). Disease recurrence was detected in bone marrow, bone marrow plus testis, testis alone and central nervous system in 16 (24·2%), 1 (1·5%), 1 (1·5%) and 1 (1·5%) patients respectively. No deaths were reported during induction. The SCMC- ALL-2005 trial for ALL patients <2 years old indicated high remission induction and low infection and treatment-related mortality rates. [ABSTRACT FROM AUTHOR]